Abstract

Introduction

Materials & Methods

Results

Discussion & Conclusion

References

Discussion
Board

1. Pate, B.D., Kawamata, T., Yamada, T., McGeer, E.G., Hewitt, K.A., Snow, B.J., Ruth, T.J., and Calne, D.B. Correlation of striatal fluorodopa uptake in the MPTP monkey with dopaminergic indices. Ann.Neurol. 34:331-338, 1993.
2. Snow, B.J., Tooyama, I., McGeer, E.G., Yamada, T., Calne, D.B., Takahashi, H., and Kimura, H. Human positron emission tomographic [¹⁸F]fluorodopa studies correlate with dopamine cell counts and levels. Ann.Neurol. 34:324-330, 1993.
3. Vanderborght, T., Kilbourn, M., Desmond, T., Kuhl, D., and Frey, K. The vesicular monoamine transporter is not regulated by dopaminergic drug treatments. Eur.J.Pharmacol. 294:577-583, 1995.
4. Wilson, J.M. and Kish, S.J. The vesicular monoamine transporter, in contrast to the dopamine transporter, is not altered by chronic cocaine self-administration in the rat. J. Neurosci. 16:3507-3510, 1996.
5. Martin, W.R.W., Palmer, M.R., Patlak, C.S., and Calne, D.B. Nigrostriatal function in humans studied with positron emission tomography. Ann.Neurol. 26:535-542, 1989.
6. Patlak, C.S. and Blasberg, R.G. Graphical evaluation of blood-to-brain transfer constants from multiple-time uptake data: generalizations. J.CBF Metab. 5:584-590, 1985.
7. Logan, J., Fowler, J.S., Volkow, N.D., Wang, G.-J., Ding, Y.-S., and Alexoff, D.L. Distribution volume ratios without blood sampling from graphical analysis of PET data. J.CBF Metab. 16:834-840, 1996.
8. Seeman, P., Guan, H.C., and Niznik, H.B. Endogenous dopamine lowers the dopamine D2 receptor density as measured by ³H raclopride: implications for positron emission tomography of the human brain. Synapse 3:96-97, 1989.
9. Volkow, N.D., Wang, G.-J., Fowler, J.S., Logan, J., Schlyer, D., Hitzeman, R., Lieberman, J., Angrist, B., Pappas, N., MacGregor, R., Burr, G., Cooper, T., and Wolf, A.P. Imaging endogenous dopamine competition with [¹¹C]raclopride in the human brain. Synapse 16:255-262, 1994.
10. Zhu MY, Juorio AV, Paterson IA, Boulton AA. Regulation of striatal aromatic L-amino acid decarboxylase: effects of blocakde or activation of dopamine receptors. Eur J Pharmacol 1993;238:157-164.
11. Cho S, Neff NH, Hadjiconstantinou M. Regulation of tyrosine hydroxylase and aromatic L-amino acid decarboxylase by dopaminergic drugs. Eur J Pharmacol 1997;323:149-157.
12. Cumming, P., Ase, A., Laliberte, C., Kuwabara, H., Gjedde, A. In vivo regulation of DOPA decarboxylase by dopamine receptor in rat brain. J.CBF Metab. 1997; 17:1254-1260.
13. Leenders, K.L., Palmer, A.J., Quinn, N., Clark, J.C., Firnau, G., Garnett, E.S., Nahmias, C., Jones, T., and Marsden, C.D. Brain dopamine metabolism in patients with Parkinson's disease measured with positron emission tomography. J. Neurol. Neurosurg. Psychiatry 49:853-860, 1986.
14. Holden, J.E., Doudet, D.J., Endres, C.J., Chan, G.L.Y., Morrison, K.S., Vingerhoets, F.J.G., Snow, B.J., Pate, B.D., Sossi, V., Buckley, K.R., and Ruth, T.J. Graphical analysis of 6-fluoro-L-dopa trapping: effect of inhibition of catechol-O-methyltransferase. J.Nucl.Med. 38:1568-1574, 1997.
15. Doudet, D.J., Chan, G.L.Y., Holden, J.E., McGeer, E.G., Aigner, T.A., Wyatt, R.J., and Ruth, T.J. 6-[¹⁸F]Fluoro-L-dopa PET studies of the turnover of dopamine in MPTP-induced parkinsonism in monkeys. Synapse 29:225-232, 1998.
16. Turjanski, N., Lees, A.J., and Brooks, D.J. In vivo studies on striatal dopamine D1 and D2 site binding in L-dopa-treated Parkinson's disease patients with and without dyskinesias. Neurology 49:717-723, 1997.

Back to the top.